Janone files international patent application for methods of using low dose naltrexone to treat chronic pain

Patent filing marks another milestone in becoming a world leader in pain management las vegas , june 28, 2023 /prnewswire/ -- janone inc. (nasdaq: jan), a biopharmaceutical company that is developing multiple drugs to treat chronic diseases like peripheral artery disease (pad) and complex regional pain syndrome (crps), has just filed an international patent application for methods of using low dose naltrexone to treat chronic pain. dr. amol soin, the chief medical officer and inventor mentioned, "this patent filing, should it issue, will bolster our plans to help treat patients suffering from complex regional pain syndrome across the globe, using our novel formulation and dosing strategy that we feel will be advantageous with our drug candidate, jan123.
JAN Ratings Summary
JAN Quant Ranking